Tumour type is decisive
Metastases generally retain the biological identity of the primary tumour. Systemic treatment is therefore guided primarily by the original tumour type and its molecular characteristics.
Biomarkers can influence treatment selection
Depending on tumour type, PD-L1, MSI/MMR and other molecular alterations may be relevant to certain immuno-oncology or targeted treatments. Which tests are useful is tumour-specific.
Combining local and systemic treatment
In selected patients, local procedures directed at individual metastases can be combined with systemic therapies. Decisions are made in a multidisciplinary setting.
Dendritic cell therapy
Dendritic-cell approaches use a different immunological strategy from checkpoint inhibitors. Their clinical evidence varies according to tumour type and protocol; a possible use should not be inferred simply from the presence of metastases.
Do not delay necessary treatment
The search for additional immunological options should not unnecessarily delay established treatments that are medically indicated. A coordinated assessment with the treating oncologist is advisable.
Have your records reviewed in context
For structured orientation, existing findings, histology, current imaging, previous treatments and – where available – molecular results can be brought together. This can help identify which questions should be clarified with the treating oncologist and which additional immuno-oncology information may be relevant.
Free individual treatment assessment